These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 33439572)

  • 1. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy.
    Lazzeri M; Duga S; Azzolini E; Fasulo V; Buffi N; Saita A; Lughezzani G; Paraboschi EM; Hurle R; Nobili A; Cecconi M; Guazzoni G; Casale P; Asselta R;
    Minerva Urol Nephrol; 2022 Feb; 74(1):77-84. PubMed ID: 33439572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis.
    Lyon M; Li J; Cullen J; Milinovich A; Kattan M; Jehi L; Sharifi N; Klein EA
    J Urol; 2022 Jan; 207(1):183-189. PubMed ID: 34433301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
    Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
    JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
    Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
    JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
    Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
    Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
    Ayodele O; Cabral HJ; McManus D; Jick S
    Clin Epidemiol; 2021; 13():661-673. PubMed ID: 34377032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
    Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
    JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Sountoulides P; Roehrborn CG; Mirone V; Schips L
    Int Urol Nephrol; 2014 Apr; 46(4):695-701. PubMed ID: 24136187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
    Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
    Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer.
    Finelli A; Komisarenko M; Martin LJ; Timilshina N; Jain K; Morris J; Zlotta A; Kulkarni G; Perlis N; van der Kwast T; Evans A; Ghai S; Fleshner N; Alibhai SMH; Hamilton RJ
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):69-76. PubMed ID: 32152437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
    Nickols NG; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Might M; Goldstein DB; Wang X; Ramoni R; Myrie K; Tran S; Ghayouri L; Tsai S; Geelhoed M; Makarov D; Becker DJ; Tsay JC; Diamond M; George A; Al-Ajam M; Belligund P; Montgomery RB; Mostaghel EA; Sulpizio C; Mi Z; Dematt E; Tadalan J; Norman LE; Briones D; Clise CE; Taylor ZW; Huminik JR; Biswas K; Rettig MB
    Trials; 2021 Jul; 22(1):431. PubMed ID: 34225789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
    Mancia G; Rea F; Ludergnani M; Apolone G; Corrao G
    N Engl J Med; 2020 Jun; 382(25):2431-2440. PubMed ID: 32356627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
    Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Jiménez-Alcaide E; García-Fuentes C; Hernández V; De la Peña E; Pérez-Fernández E; Castro A; Caballero-Perea B; Guijarro A; Llorente C
    Prostate; 2021 Dec; 81(16):1349-1354. PubMed ID: 34517429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
    DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
    Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.